APPLY NOW TO BECOME A MAxL TEAM!

- The Bio^M MAxL - Daiichi Sankyo Golden Ticket Program 

Bio^M MAxL and global healthcare company Daiichi Sankyo have launched a Golden Ticket to accelerate novel therapeutics and platform technologies in oncology, neuroscience, and ophthalmology. The winning team receives one year of free access to MAxL’s state-of-the-art lab and co-working space to advance its research.

MAxL's Golden Ticket program enables an outstanding founding team to advance its research work in the incubator's state-of-the-art laboratory and co-working space free of charge for one year. The team also benefits from a tailored mentoring and networking program - including valuable contacts to investors.

Daiichi Sankyo is actively involved in the selection process of the applicant teams and offers the winning start-up direct insights into the industry as well as access to its global network of experts and industry contacts.

Apply now if you are passionate about making a difference in the fields of:

Modality & Technology Area:

• RNA targeting therapeutics

• Cell & Gene therapy and associated technologies

• Chemical modalities and biologics designed to induce proximity

• Delivery technology to specific organs & cells

• Innovative technologies enabling the penetration of biologics into cells

Oncology Area:

• Innovative tumor-specific modalities including conditional activation and targeted delivery of biologics

• Distinctive techniques for identifying tumor-specific antigens and binders

• Chemical compounds exhibiting novel anti-cancer mechanisms

Specialty Medicine Area:

• Innovative research aimed at identifying disease-relevant targets through the use of patient tissue samples in the fields of central nervous system, cardiovascular, and ophthalmology

• Development of novel in vitro and in vivo models that accurately replicate human pathological mechanisms and conditions

The Prize:

As the winner, you’ll unlock a wealth of opportunities designed to propel your idea:

• 12-month rent-free incubator space in Martinsried, Munich

• Access to MAxL’s program to support commercial de-risking

• Mentoring & support from specialist business coaches

• Mentoring & support from Daiichi Sankyo’s drug discovery & development experts

• Access to Bio^M’s extensive industry and investor’s network

• Access to Bio^M’s vibrant ecosystem and events

How to apply:

Closing date for applications is 28 July 2025 If you’re working on ground-breaking solutions in these critical areas, we want to support you in turning your vision into reality. This is your chance to harness our world-class resources and take your innovation to the next level. Submit your application and once reviewed, shortlisted candidates will be invited to a pitching event following the submission deadline.

Find the application form and more information about the application here:

• Application form - Bio^M MAxL - Daiichi Sankyo Golden Ticket Program

• 2025 Presentation for Applicants - Bio^M MAxL - Daiichi Sankyo Golden Ticket Program 2025

Please send your completed application form to Regina Abendroth: abendroth@remove-this.bio-m.org. 

Selection process

All applications will be reviewed by the Daiichi Sankyo and MAxL selection committee

• Shortlisted candidates will be invited to a pitching event

• The winner startup will be announced in October 2025

• The selected winner startup shall be notified by MAxL and will enter into a direct contractual agreement with MAxL/BioM

• The successful candidate will move into MAxL until January 2026 the latest

If you should have any questions, please contact Regina Abendroth: abendroth@remove-this.bio-m.org or Elisabeth Harbich: harbich@remove-this.bio-m.org.

About Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 30 countries/regions around the world. With a legacy of innovation since 1899, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our ca. 20,000 employees worldwide, we create innovative new and generic medicines. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

To become a golden ticket or another type of sponsor, please check out MAxL's sponsoring opportunities.